March 6, 2020

Jacob Chacko, M.D.
President and Chief Executive Officer
Oric Pharmaceuticals, Inc.
240 E. Grand Ave, 2nd Floor
South San Francisco, CA 94080

       Re: Oric Pharmaceuticals, Inc.
           Registration Statement on Form S-1
           Filed February 28, 2020
           CIK No. 0001796280

Dear Dr. Chacko:

       We have reviewed your registration statement and have the following
comment. In our
comment, we may ask you to provide us with information so we may better
understand your

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comment applies to your facts
circumstances or do not believe an amendment is appropriate, please tell us why
in your

       After reviewing any amendment to your registration statement and the
information you
provide in response to our comment, we may have additional comments.

Form S-1 filed February 28, 2020

Capitalization, page 83

1.     Please tell us how you determined the inclusion of the 118,301 shares
resulting from the
       early option exercise in the number of shares issued and outstanding was
       appropriate to arrive to the pro forma, and pro forma as adjusted
presentation. You also
       disclose on page 8 that you expect these shares will be outstanding
after the offering.
       However, it appears from your disclosure elsewhere that these are shares
from the future
       exercise of options that are not yet vested and therefore not available
to be
       outstanding. Please revise to clarify this apparent inconsistency.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.
 Jacob Chacko, M.D.
Oric Pharmaceuticals, Inc.
March 6, 2020
Page 2

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration

       You may contact Ibolya Ignat at 202-551-3636 or Kevin Vaughn at
202-551-3494 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jeffrey Gabor at 202-551-2544 or Celeste Murphy at 202-551-3257 with
any other

FirstName LastNameJacob Chacko, M.D.
                                                           Division of
Corporation Finance
Comapany NameOric Pharmaceuticals, Inc.
                                                           Office of Life
March 6, 2020 Page 2
cc:       Melissa Rick, Esq.
FirstName LastName